

## Infektiöse Endokarditis – Update. Teil 2

### Endocardite infectieuse – Update. 2ème partie

#### Literatur / Références

1. Fowler V.G., Scheld W.M., Tenenbaum A.S., Endocarditis and intravascular infections, in Douglas and Bennett's principles and practice of infectious diseases. Elsevier. 2005:975–1022.
2. Lefort, A., et al., Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and *Streptococcus milleri*: a multicenter study in France. *Arch Intern Med.* 2002;162(21):2450–6.
3. Sambola, A., et al., *Streptococcus agalactiae* infective endocarditis: analysis of 30 cases and review of the literature, 1962–1998. *Clin Infect Dis.* 2002;34(12):1576–84.
4. Falagas, M.E., D.K. Matthaiou, and I.A. Bliziotis, The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. *J Antimicrob Chemother.* 2006;57(4):639–47.
5. Wilson, W.R., et al., Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. *Ann Intern Med.* 1984;100(6):816–23.
6. Olaison, L. and K. Schadewitz, Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used? *Clin Infect Dis.* 2002;34(2):159–66.
7. Gavalda, J., et al., Brief communication: treatment of *Enterococcus faecalis* endocarditis with ampicillin plus ceftriaxone. *Ann Intern Med.* 2007;146(8):574–9.
8. Levine, D.P., Clinical experience with daptomycin: bacteraemia and endocarditis. *J Antimicrob Chemother.* 2008;62 Suppl 3:iii35–39.
9. Das, I., T. Saluja, and R. Steeds, Use of daptomycin in complicated cases of infective endocarditis. *Eur J Clin Microbiol Infect Dis.* 2011;30(6):807–12.
10. Arias, C.A., G.A. Contreras, and B.E. Murray, Management of multidrug-resistant enterococcal infections. *Clin Microbiol Infect.* 2010;16(6):555–62.
11. Ribera, E., et al., Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided *Staphylococcus aureus* endocarditis. A randomized, controlled trial. *Ann Intern Med.* 1996;125(12):969–74.
12. Heldman, A.W., et al., Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. *Am J Med.* 1996;101(1):68–76.
13. Korzeniowski, O. and M.A. Sande, Combination antimicrobial therapy for *Staphylococcus aureus* endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. *Ann Intern Med.* 1982;97(4):496–503.
14. Cosgrove, S.E., et al., Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis.* 2009;48(6):713–21.
15. Howden, B.P., et al., Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother.* 2006;50(9):3039–47.
16. Ullil, R, Treatment of multiresistant Gram positive endocarditis, *Infez Med.* 2009;17 Suppl 3:13–24.
17. (CDC), C.f.D.C.a.P., Vancomycin-resistant *Staphylococcus aureus*--Pennsylvania, 2002. *MMWR Morb Mortal Wkly Rep.* 2002;51(40):902.
18. (CDC), C.f.D.C.a.P., *Staphylococcus aureus* resistant to vancomycin--United States, 2002. *MMWR Morb Mortal Wkly Rep.* 2002;51(26):565–7.
19. Levine, D.P. and K.C. Lamp, Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. *Am J Med.* 2007;120(10 Suppl 1):S28–33.
20. Kaya, S., et al., Treatment of left-sided Gram-positive endocarditis with daptomycin, Poster 1848, ECCMID 2012.
21. Sacar, M., et al., Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant *Staphylococcus aureus*. *Tex Heart Inst J.* 2010;37(4):400–4.
22. Murdoch, D.R., et al., Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. *Arch Intern Med.* 2009;169(5):463–73.
23. Head, S.J., et al., Surgery in current therapy for infective endocarditis. *Vasc Health Risk Manag.* 2011;7:255–63.
24. Prendergast, B.D. and P. Tornos, Surgery for infective endocarditis: who and when? *Circulation.* 2010;121(9):1141–52.
25. Kim, D.H., et al., Impact of early surgery on embolic events in patients with infective endocarditis. *Circulation.* 2010;122(11 Suppl):S17–22.
26. Thuny, F., et al., The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. *Eur Heart J.* 2011;32(16):2027–33.

27. San Roman, J.A., et al., Rationale, design, and methods for the early surgery in infective endocarditis study (ENDO-VAL 1): a multicenter, prospective, randomized trial comparing the state-of-the-art therapeutic strategy versus early surgery strategy in infective endocarditis. *Am Heart J.* 2008;156(3):431–6.
28. San Roman, J.A., et al., Prognostic stratification of patients with left sided endocarditis determined at admission. *Am J Med.* 2007;120(369):e1–e7.
29. Habib G, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. *Eur Heart J.* 2009;30(19):2369–413.